Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Mar 20;40(9):921-923.
doi: 10.1200/JCO.21.02465. Epub 2021 Nov 12.

Taking a BiTE Out of CAR-T Cell Efficacy

Haley M Newman  1 , David T Teachey  1   2
Affiliations
Editorial

Taking a BiTE Out of CAR-T Cell Efficacy

Haley M Newman et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

David T. TeacheyConsulting or Advisory Role: SobiResearch Funding: Novartis (Inst), Beam Therapeutics (Inst), NeoImmuneTech (Inst)No other potential conflicts of interest were reported.

Comment on

  • Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL.
    Myers RM, Taraseviciute A, Steinberg SM, Lamble AJ, Sheppard J, Yates B, Kovach AE, Wood B, Borowitz MJ, Stetler-Stevenson M, Yuan CM, Pillai V, Foley T, Chung P, Chen L, Lee DW, Annesley C, DiNofia A, Grupp SA, John S, Bhojwani D, Brown PA, Laetsch TW, Gore L, Gardner RA, Rheingold SR, Pulsipher MA, Shah NN. Myers RM, et al. J Clin Oncol. 2022 Mar 20;40(9):932-944. doi: 10.1200/JCO.21.01405. Epub 2021 Nov 12. J Clin Oncol. 2022. PMID: 34767461 Free PMC article.

References

    1. Myers RM, Taraseviciute A, Steinberg SM, et al. Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL J Clin Oncol 40932–9442022 - PMC - PubMed
    1. Kadauke S, Myers RM, Li Y, et al. Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: A prospective clinical trial J Clin Oncol 39920–9302021 - PMC - PubMed
    1. Dourthe M-E, Rabian F, Yakouben K, et al. Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia Leukemia 353383–33932021 - PubMed
    1. Pillai V, Muralidharan K, Meng W, et al. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy Blood Adv 33539–35492019 - PMC - PubMed
    1. Gardner R, Wu D, Cherian S, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy Blood 1272406–24102016 - PMC - PubMed

Substances